Secondary outcomes
UC
Secondary endpoints included mortality up to day 29, length of hospital stay, level of care, changes in oxygen requirement/delivery and changes in severity measured by ordinal scale, NEWS2 and SOFA scores. In summary, there were no significant differences between UC and anakinra or between UC and tocilizumab for any measure (